Poxel SA's oral type 2 diabetes innovative therapy imeglimin Phase 3 clinical trial gets positive top-line results

today, Poxel SAcompany(http://announced that the company's innovative oral type 2 diabetes treatment, imeglimin, has achieved positive top-line results in the Open Label Extension Research section of phase 3 clinicaltrial(http://TIMES3About imeglimin
poxel developed by the world's first glimin-typedrug(http://It has a completely new mechanism of actionScientists at Poxel believe mitochondria is one of the causes of diabetes, and imeglimin is expected to reverse the potential causes of the disease by improving mitochondrial bioenepicsImeglimin acts on the three major organs of the liver, muscles, and pancreas, and is expected to promote insulin secretion, increase insulin sensitivity, and inhibit sugar isogenesisIn April, imeglimin reached its primary clinical endpoint in a randomized double-blind, placebo-controlled TIMES 1 clinical trial, reducing patients' glycated hemoglobin (HbA1c) levels by 0.87 percent compared to baselineIn the TIME 3 clinical trial, imeglimin was used in combination with insulin to treat patients with type 2 diabetes who had a poor response to insulin monotherapyThe first 16 weeks of the trial were randomized double-blind, with a placebo-controlled trial, and the results showed that adding imeglimin to an insulin treatment regimen was able to reduce HbA1c levels by 0.6% compared to the control groupIn the open label extension study, all patients were treated with imeglimin and insulinThe results showed that after 36 weeks of treatment, the levels of HbA1c were reduced by 0.64% and 0.54%, respectively, compared to baselines in patients in the imeglimin group or placebo group